Diclofenac

[9-30-2025] The Food and Drug Administration is advising consumers not to purchase or use Me Vale Madre, a product promoted and sold for migraine and stress pain on various websites, including ebay.com, and possibly in some retail stores. FDA laboratory analysis confirmed that Me Vale Madre contains acetaminophen and diclofenac not listed on the product label. Acetaminophen is a medicine used to reduce pain and fever that is found in many prescription and over-the-counter (OTC) drug products. Use of the product Me Vale Madre poses a serious threat to consumers because it may result in unintentional acetaminophen overdose, especially if it is used in combination with other acetaminophen-containing products. Acetaminophen overdose can cause liver damage (hepatoxicity), ranging in severity from abnormalities in liver function to acute liver failure, and even death. People who experience acetaminophen overdose may not seek prompt medical attention because the symptoms of liver damage can take several days to emerge, even in severe cases. Acetaminophen may also cause serious skin reactions. Symptoms may include skin reddening, rash and blisters. Diclofenac is a non-steroidal anti-inflammatory drug (NSAID). NSAIDs may cause increased risk of cardiovascular events, such as heart attack and stroke, as well as serious gastrointestinal damage, including bleeding, ulceration and fatal perforation of the stomach and intestines. This hidden drug ingredient may also interact with other medications and significantly increase the risk of adverse events, particularly when consumers use multiple NSAID-containing products. Health care professionals and consumers should report adverse events or side effects related to the use of this product to FDA's MedWatch Safety Information and Adverse Event Reporting Program: This notification is to inform the public of products potentially marketed as dietary supplements or conventional foods with hidden drug ingredients and chemicals. These products are typically promoted for sexual enhancement, weight loss, pain relief and body building and are often represented as being all natural. Consumers should exercise caution before purchasing these products. FDA is unable to test and identify all products marketed as dietary supplements that have potentially harmful hidden ingredients. For more information: Content current as of: 09/30/2025 Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

TUESDAY, Sept. 16, 2025 -- For presbyopia management, pilocarpine-diclofenac eye drops provide dose-dependent improvement, which can be sustained over two years, according to a study presented at the annual Congress of the European Society of Cataract and Refractive Surgeons, held from Sept. 12 to 16 in Copenhagen, Denmark. Giovanna Benozzi, M.D., from the Centro de Investigación Avanzada de la Presbicia in Buenos Aires, Argentina, and colleagues conducted a retrospective study using an electronic medical record system to examine the efficacy and safety of pilocarpine-diclofenac eye drops at concentrations of 1, 2, and 3 percent for management of presbyopia. A total of 766 patients were treated with pilocarpine-diclofenac eye drops administered twice daily. The researchers found a significant improvement in uncorrected near visual acuity across all concentrations: 99 percent of 148 patients in the 1 percent group achieved at least two-line improvement; 69 percent of 248 patients in the 2 percent group achieved a at least three-line improvement; and 84 percent of 370 patients in the 3 percent group achieved at least three-line improvement. The effect lasted up to two years, with a median duration of 434 days. During 167,000 participant-treatment days, there were no serious adverse events. Temporary dim vision, instillation irritation, and headache were the most common mild and transient events (32, 3.7, and 3.8 percent, respectively). Ocular adverse events were mild; none of the patients discontinued treatment. "Importantly, this treatment is not intended to replace surgical interventions, but rather to serve as a valuable solution for patients who need safe, effective, and personalized alternatives and seek freedom from the inconvenience of eyewear," Benozzi said in a statement. "Eye care professionals now have an evidence-based pharmacological option that expands the spectrum of presbyopia care beyond glasses and surgery.” Press Release More Information